Literature DB >> 13276822

Current trends in cancer chemotherapy.

B E HALL, F M WILLETT, T V FEICHTMEIR, E B REED, W F DOWLING.   

Abstract

Current trends in the search for chemical compounds having an inhibitory action on the growth of malignant cells are reviewed in this article. Several agents are sufficiently promising that clinical trials with them are in progress. One of these, an aromatic nitrogen mustard (C.B. 1348), appears to be useful as an adjunctive therapeutic measure in patients with malignant lymphoma, chronic lymphocytic leukemia, and mycosis fungoides who have become refractory to other methods of treatment. The introduction of certain purine antagonists, of which 6-mercaptopurine has been given the most extensive clinical trial, has opened up a new field of experimental and clinical investigation. 6-mercaptopurine and related compounds appear to be particularly useful in the treatment of acute leukemia in adults, but they are also useful, together with the folic acid antagonists and the steroid hormones, in the management of acute leukemia in children. While at present chemotherapeutic agents currently under investigation rarely cause significant regression of inoperable primary or metastatic solid tumors, the possibility of eventual more effective control in many types of malignant disease is not as dismal as it was a decade ago.

Entities:  

Keywords:  NEOPLASMS/therapy

Mesh:

Substances:

Year:  1956        PMID: 13276822      PMCID: PMC1532858     

Source DB:  PubMed          Journal:  Calif Med        ISSN: 0008-1264


  18 in total

1.  Chemotherapy of leukemia and allied disorders.

Authors:  B E HALL
Journal:  Med Clin North Am       Date:  1953-11       Impact factor: 5.456

2.  Triethylene melamine in clinical cancer chemotherapy.

Authors:  A GELLHORN; M M KLIGERMAN; I JAFFE
Journal:  Am J Med       Date:  1952-10       Impact factor: 4.965

3.  Clinical observations on the use of triethylenemelamine.

Authors:  E D BAYRD; J M STICKNEY; B E HALL; C H WATKINS
Journal:  Cancer       Date:  1952-03       Impact factor: 6.860

4.  Prevention of toxicity of massive doses of A-methopterin by citrovorum factor.

Authors:  J H BURCHENAL; G M BABCOCK
Journal:  Proc Soc Exp Biol Med       Date:  1951-02

5.  The effects of the folic acid antagonists and 2,6-diaminopurine on neoplastic disease, with special reference to acute leukemia.

Authors:  J H BURCHENAL; D A KARNOFSKY; E M KINGSLEY-PILLERS; C M SOUTHAM; W P L MYERS; G C ESCHER; L F CRAVER; H W DARGEON; C P RHOADS
Journal:  Cancer       Date:  1951-05       Impact factor: 6.860

6.  Triethylene melamine in the treatment of neoplastic disease; a compound with nitrogen-mustardlike activity suitable for oral and intravenous use.

Authors:  D A KARNOFSKY; J H BURCHENAL; G C ARMISTEAD; C M SOUTHAM; J L BERNSTEIN; L F CRAVER; C P RHOADS
Journal:  AMA Arch Intern Med       Date:  1951-04

7.  Nitrogen mustards in the treatment of neoplastic disease.

Authors:  D A KARNOFSKY
Journal:  Adv Intern Med       Date:  1950

8.  The clinical use of triethylene melamine.

Authors:  S C KRAVITZ; H D DIAMOND; L F CRAVER
Journal:  Blood       Date:  1952-07       Impact factor: 22.113

9.  Treatment of leukemia with triethylene thiophosphoramide (thio-TEPA); preliminary results in experimental and clinical leukemia.

Authors:  H SHAY; C ZARAFONETIS; N SMITH; I WOLDOW; D C SUN
Journal:  AMA Arch Intern Med       Date:  1953-11

10.  Use of pituitary adrenocorticotropic hormone (ACTH) and cortisone in lymphomas and leukemias.

Authors:  O H PEARSON; L P ELIEL
Journal:  J Am Med Assoc       Date:  1950-12-16
View more
  1 in total

Review 1.  Decreased Disposition of Anticancer Drugs Predominantly Eliminated via the Liver in Patients with Renal Failure.

Authors:  Kenichi Fujita; Natsumi Matsumoto; Hiroo Ishida; Yutaro Kubota; Shinichi Iwai; Motoko Shibanuma; Yukio Kato
Journal:  Curr Drug Metab       Date:  2019       Impact factor: 3.731

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.